7-Aug-2026
Top Executive Makes Bold Move With Fresh Anixa Biosciences Stock Buy
TipRanks (Mon, 3-Aug 10:09 PM ET)
PRNewswire (Mon, 6-Jul 8:30 AM ET)
PRNewswire (Mon, 29-Jun 8:46 AM ET)
PRNewswire (Fri, 26-Jun 9:11 AM ET)
PRNewswire (Thu, 11-Jun 9:05 AM ET)
PRNewswire (Mon, 1-Jun 9:08 AM ET)
/C O R R E C T I O N -- Anixa Biosciences, Inc./
PRNewswire (Mon, 11-May 11:49 AM ET)
PRNewswire (Mon, 11-May 8:55 AM ET)
ANIX Advances Breast Cancer Vaccine After Phase 1 Data Shows 74% Immune Response Rate
Market Chameleon (Fri, 12-Dec 2:08 AM ET)
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Anixa Biosciences trades on the NASDAQ stock market under the symbol ANIX.
As of August 7, 2026, ANIX stock price declined to $3.42 with 148,147 million shares trading.
ANIX has a beta of 0.56, meaning it tends to be less sensitive to market movements. ANIX has a correlation of 0.01 to the broad based SPY ETF.
ANIX has a market cap of $116.36 million. This is considered a Micro Cap stock.
In the last 3 years, ANIX traded as high as $5.46 and as low as $2.07.
The top ETF exchange traded funds that ANIX belongs to (by Net Assets): VTI, VXF, IWC.
ANIX has underperformed the market in the last year with a price return of +13.6% while the SPY ETF gained +23.5%. However, in the short term, ANIX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.5% vs +6.0% return in SPY. But in the last 2 weeks, ANIX shares have been beat by the market, returning -7.6% compared to an SPY return of +4.6%.
ANIX support price is $3.27 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIX shares will trade within this expected range on the day.